Nutrien Ltd vs Novartis AG — how do they compare? Nutrien Ltd trades at $66.65 (market cap $32.05B), while Novartis AG trades at $152.73 (market cap $295.37B). The key difference: Novartis AG is far larger — about 9.2× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| NTR | NVS | |
|---|---|---|
Market Cap | $32.05B | $295.37B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $168.62 |
52-Week Low | $53.64 | $119.31 |
Enterprise Value | $43.86B | $336.69B |
Dividend Yield | 3.27% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $66.31, up 2.93% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, though revenues benefited from higher potash prices. Fundamentals show solid profitability with 8.44% net margin and reasonable valuation at P/E of 13.62. Recent dividend declarations of $0.55 per share demonstrate shareholder returns commitment.
NTR presents value opportunity with analyst consensus target of $76.17 (15% upside) and strong buy ratings (61%). However, earnings volatility, declining cash flow trends, and agricultural cycle sensitivity pose risks. The stock's appeal hinges on execution amid input cost pressures and global fertilizer demand recovery.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →